| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GeneDx Holdings Corp. - WGS |
NEW YORK, NY / ACCESS Newswire / February 27, 2025 / Pomerantz LLP is investigating claims on behalf of investors of GeneDx Holdings Corp ("GeneDx" or the "Company") (NASDAQ:WGS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accessnewswire.com |
2025-02-27 12:30:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GeneDx Holdings Corp. - WGS |
NEW YORK , Feb. 25, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of GeneDx Holdings Corp ("GeneDx" or the "Company") (NASDAQ: WGS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
prnewswire.com |
2025-02-25 19:00:00 |
Czytaj oryginał (ang.) |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating GeneDx Holdings Corp. (WGS) And Encourages Shareholders to Connect |
NEW YORK, NY / ACCESS Newswire / February 25, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of GeneDx Holdings Corp. ("GeneDx" or "the Company") (NASDAQ:WGS). Investors who purchased GeneDx securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/WGS. |
accessnewswire.com |
2025-02-25 12:00:00 |
Czytaj oryginał (ang.) |
| Landmark Seqfirst-neo Study Showcases the Significant Impact of Genomic Testing in the NICU, Revealing Gaps in Current Protocols |
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS) today announced that the American Journal of Human Genetics published peer-reviewed research from the Seqfirst-neo study. |
businesswire.com |
2025-02-24 13:00:00 |
Czytaj oryginał (ang.) |
| 4 Healthcare Stocks to Buy as the Sector Stages a Comeback |
Buy healthcare stocks like WGS, THC, RIGL and ENSG for steady returns as the focus shifts to the incoming Trump administration's healthcare policies. |
zacks.com |
2025-02-24 11:15:30 |
Czytaj oryginał (ang.) |
| GENEDX HOLDINGS (WGS) Upgraded to Strong Buy: Here's What You Should Know |
GENEDX HOLDINGS (WGS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
zacks.com |
2025-02-21 15:00:29 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GeneDx Holdings Corp. - WGS |
NEW YORK CITY, NY / ACCESS Newswire / February 21, 2025 / Pomerantz LLP is investigating claims on behalf of investors of GeneDx Holdings Corp ("GeneDx" or the "Company") (NASDAQ:WGS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accessnewswire.com |
2025-02-21 12:00:00 |
Czytaj oryginał (ang.) |
| GeneDx Holdings Corp. (WGS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation |
NEW YORK, NY / ACCESS Newswire / February 20, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of GeneDx Holdings Corp. ("GeneDx" or "the Company") (NASDAQ:WGS). Investors who purchased GeneDx securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/WGS. |
accessnewswire.com |
2025-02-20 12:00:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GeneDx Holdings Corp. - WGS |
NEW YORK, NY / ACCESS Newswire / February 19, 2025 / Pomerantz LLP is investigating claims on behalf of investors of GeneDx Holdings Corp ("GeneDx" or the "Company") (NASDAQ:WGS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accessnewswire.com |
2025-02-19 17:00:00 |
Czytaj oryginał (ang.) |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating GeneDx Holdings Corp. (WGS) And Encourages Investors to Connect |
NEW YORK, NY / ACCESS Newswire / February 19, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of GeneDx Holdings Corp. ("GeneDx" or "the Company") (NASDAQ:WGS). Investors who purchased GeneDx securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/WGS. |
accessnewswire.com |
2025-02-19 12:00:00 |
Czytaj oryginał (ang.) |
| Reviewing GeneDx Holdings: Exome Testing And EPIC Aura Integration Make It A GARP 'Buy' |
GeneDx excels in comprehensive genome and exome testing using a vast genetic database linking 400+ diseases. The company cuts diagnostic times from years to days, enhancing patient outcomes and reducing healthcare costs. WGS basically targets a $45 billion genetic testing market with growth in pediatric, NICU, and adult segments via EPIC Aura integration. |
seekingalpha.com |
2025-02-19 11:29:05 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GeneDx Holdings Corp. - WGS |
NEW YORK , Feb. 18, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of GeneDx Holdings Corp ("GeneDx" or the "Company") (NASDAQ: WGS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
prnewswire.com |
2025-02-18 20:27:00 |
Czytaj oryginał (ang.) |
| GeneDx CEO on pediatric genetic testing, future of genome sequencing and share surge |
Katherine Stueland, GeneDx CEO, joins 'Closing Bell' to discuss company earnings and the future of genome sequencing. |
youtube.com |
2025-02-18 17:54:27 |
Czytaj oryginał (ang.) |
| GeneDx Holdings Corp. (WGS) Q4 2024 Earnings Call Transcript |
GeneDx Holdings Corp. (NASDAQ:WGS ) Q4 2024 Results Conference Call February 18, 2025 8:30 AM ET Company Participants Sabrina Dunbar - Investor Relations Katherine Stueland - President and Chief Executive Officer Kevin Feeley - Chief Financial Officer Conference Call Participants Dan Brennan - TD Cowen William Bonello - Craig-Hallum Capital Group Matt Stanton - Jefferies Matt Sykes - Goldman Sachs Mark Massaro - BTIG Brandon Couillard - Wells Fargo Operator Good day, and thank you for standing by. Welcome to the GeneDx Fourth Quarter 2024 Earnings Conference Call. |
seekingalpha.com |
2025-02-18 13:02:01 |
Czytaj oryginał (ang.) |
| Bronstein, Gewirtz & Grossman, LLC Encourages GeneDx Holdings Corp. (WGS) Stockholders to Inquire about Securities Investigation |
NEW YORK, NY / ACCESS Newswire / February 18, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of GeneDx Holdings Corp. ("GeneDx" or "the Company") (NASDAQ:WGS). Investors who purchased GeneDx securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/WGS. |
accessnewswire.com |
2025-02-18 12:00:00 |
Czytaj oryginał (ang.) |
| GeneDx Holdings Corp. (WGS) Q4 Earnings and Revenues Surpass Estimates |
GeneDx Holdings Corp. (WGS) came out with quarterly earnings of $0.70 per share, beating the Zacks Consensus Estimate of $0.20 per share. This compares to loss of $0.59 per share a year ago. |
zacks.com |
2025-02-18 10:21:08 |
Czytaj oryginał (ang.) |
| GeneDx Reports Fourth Quarter and Full Year 2024 Financial Results and Issues Guidance for Full Year 2025 |
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx Holdings Corp. (Nasdaq: WGS) today reported its financial results for the fourth quarter and full year of 2024. |
businesswire.com |
2025-02-18 08:00:00 |
Czytaj oryginał (ang.) |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against GeneDx Holdings Corp. (WGS) and Encourages Investors to Learn More About the Investigation |
NEW YORK, NY / ACCESS Newswire / February 17, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of GeneDx Holdings Corp. ("GeneDx" or "the Company") (NASDAQ:WGS). Investors who purchased GeneDx securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/WGS. |
accessnewswire.com |
2025-02-17 12:00:00 |
Czytaj oryginał (ang.) |
| GeneDx Holdings Corp. (WGS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation |
NEW YORK, NY / ACCESS Newswire / February 16, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of GeneDx Holdings Corp. ("GeneDx" or "the Company") (NASDAQ:WGS). Investors who purchased GeneDx securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/WGS. |
accessnewswire.com |
2025-02-16 12:00:00 |
Czytaj oryginał (ang.) |
| GeneDx Holdings Corp. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details - WGS |
NEW YORK, NY / ACCESS Newswire / February 14, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of GeneDx Holdings Corp. ("GeneDx Holdings Corp.") (NASDAQ:WGS) concerning possible violations of federal securities laws. Grizzly Research ("Grizzly") published a report on February 5, 2025, entitled "Insiders Attest That GeneDx (Nasdaq: WGS) Is Actively Committing Widespread Fraud". |
accessnewswire.com |
2025-02-14 12:45:00 |
Czytaj oryginał (ang.) |
| Meta Stock, Energy Plays Lead Five Leaders Rebounding Bullishly |
Meta Platforms leads five stocks flashing entries as they rebound above key moving averages within consolidations. The post Meta Stock, Energy Plays Lead Five Leaders Rebounding Bullishly appeared first on Investor's Business Daily. |
investors.com |
2025-01-04 11:15:54 |
Czytaj oryginał (ang.) |
| Best-Performing Stocks Of 2024 |
Best-Performing Stocks Of 2024 |
seekingalpha.com |
2025-01-03 01:46:00 |
Czytaj oryginał (ang.) |
| GeneDx Strengthens Executive Leadership Team with Bryan Dechairo Named Chief Operating Officer |
STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced the appointment of Bryan Dechairo as Chief Operating Officer, effective immediately. In the newly created role, Bryan will report to Katherine Stueland, CEO and President, and will serve on the company's executive leadership team. As Chief Operating Officer, Bryan will oversee Product & Technology, Operations, Medical Affairs, Innovation, and the. |
businesswire.com |
2025-01-02 18:01:00 |
Czytaj oryginał (ang.) |
| GeneDx to Present at the 43rd Annual J.P. Morgan Healthcare Conference |
STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will participate in the 43rd Annual J.P. Morgan Healthcare Conference from January 12-16 in San Francisco, CA. Management will participate in a presentation on Wednesday, January 15, 2025, at 4:30 p.m. PT. Live and archived webcasts will be available on the “Events” section of the GeneDx investor relations website at ir.genedx. |
businesswire.com |
2024-12-16 18:05:00 |
Czytaj oryginał (ang.) |
| This Once Ultracheap Biotech Stock Rockets 2,762%, Nears Buy Point After Big Earnings Win |
Biotech stock GeneDx soared 50% after earnings on Oct. 29. Shares of the genetic testing company have soared 2,762% year to date. |
investors.com |
2024-11-25 15:26:46 |
Czytaj oryginał (ang.) |
| GeneDx to Participate in Upcoming Investor Conference |
STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS) today announced that company management will participate in the Piper Sandler 36th Annual Healthcare Conference. |
businesswire.com |
2024-11-22 18:05:00 |
Czytaj oryginał (ang.) |
| GeneDx Announces Heidi Chen as Chief Legal Officer and Corporate Secretary |
STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced the appointment of Heidi Chen as Chief Legal Officer, effective November 25, 2024. In her role, Heidi will report to Katherine Stueland, CEO and President, and will serve on the executive leadership team. With over 30 years of experience, Heidi will lead all legal, compliance, and policy functions at GeneDx and will provide strategic counsel on corpor. |
businesswire.com |
2024-11-18 10:30:00 |
Czytaj oryginał (ang.) |
| Meet the Healthcare Stock That Produced Nvidia-Sized Gains in Less Than a Year |
Meet the Healthcare Stock That Produced Nvidia-Sized Gains in Less Than a Year |
fool.com |
2024-11-16 06:54:00 |
Czytaj oryginał (ang.) |
| New GeneDx Study Reveals Racial Disparities in Genetic Diagnosis Due to Systemic Barriers, Not Diagnostic Yields |
STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced the results of an extensive study shedding light on the critical issue of racial disparities in access to an accurate genetic diagnosis. The study, a collaboration among GeneDx, The University of Washington, Brotman Baty Institute for Precision Medicine, Geisinger and Seattle Children's Hospital, was conducted on nearly 187,000 samples performed and a. |
businesswire.com |
2024-11-07 18:35:00 |
Czytaj oryginał (ang.) |
| GeneDx to Highlight Key Research Findings at American Society of Human Genetics (ASHG) Annual Meeting |
STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced its scientific contributions at the 2024 American Society of Human Genetics (ASHG) annual meeting. GeneDx data will be presented across six platform presentations and five posters and will unveil findings from key research initiatives constructed on the backbones of its industry leading diverse dataset of more than 700,000 clinical exome and genomes. |
businesswire.com |
2024-11-04 18:35:00 |
Czytaj oryginał (ang.) |
| 3 Stocks to Buy for Stellar Earnings Acceleration in November |
Stocks like Snap, GeneDx Holdings and Leonardo DRS exhibit solid earnings acceleration. |
zacks.com |
2024-11-04 18:05:15 |
Czytaj oryginał (ang.) |
| Best Momentum Stocks to Buy for November 4th |
WGS, CVNA and NBBK made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on November 4, 2024. |
zacks.com |
2024-11-04 13:01:24 |
Czytaj oryginał (ang.) |
| New Strong Buy Stocks for November 4th |
CFFN, VLRS, NBBK, WGS and ISBA have been added to the Zacks Rank #1 (Strong Buy) List on November 4, 2024. |
zacks.com |
2024-11-04 08:46:16 |
Czytaj oryginał (ang.) |
| Natera And GeneDx: Outperforming Market Powered By Precision Medicines Tailwinds |
The precision medicine market is projected to grow from $91.72 billion in 2024 to $246.3 billion by 2033, fueled by advancements in genomic technologies. In the last year, Natera, Inc. and GeneDx Holdings Corp. have outperformed the market and beaten analysts expectations. Natera's oncology tests driving revenue growth and GeneDx focusing on newborn rare disease diagnostics. Both firms have been improving financial metrics, with Natera showing strong revenue growth driven by oncology tests in Q2 2024, while GeneDx achieved profitability in Q3 2024. |
seekingalpha.com |
2024-10-31 20:11:45 |
Czytaj oryginał (ang.) |
| GeneDx Holdings: Phenomenal Gains, More Upside Potential In Medium Term |
GeneDx Holdings Corp. stock has risen by a scarcely believable >3,000% across the past year. The company provides exome sequencing products that can be used to search for and diagnose hundreds of genetic conditions. The company's Q3 earnings led to a >50% uplift in the share price this week, with ~$287 revenues pledged for 2024, and a gross margin of >60%. |
seekingalpha.com |
2024-10-30 17:10:05 |
Czytaj oryginał (ang.) |
| GeneDx Holdings Corp. (WGS) Q3 2024 Earnings Call Transcript |
GeneDx Holdings Corp. (NASDAQ:WGS ) Q3 2024 Earnings Conference Call October 29, 2024 8:30 AM ET Company Participants Sabrina Dunbar - Investor Relations Katherine Stueland - President and Chief Executive Officer Kevin Feeley - Chief Financial Officer Conference Call Participants Daniel Brennan - TD Cowen William Bonello - Craig Hallum Capital Group Mark Massaro - BTIG Matthew Sykes - Goldman Sachs Group, Inc. Brandon Couillard - Wells Fargo Securities Matthew Stanton - Jefferies Operator Thank you for standing by, and welcome to the GeneDx Third Quarter 2024 Earnings Conference Call. At this time all participants are in a listen-only mode and after the speaker's presentation we will have a question-and-answer session Keep in mind that this call is being recorded. |
seekingalpha.com |
2024-10-29 20:46:04 |
Czytaj oryginał (ang.) |
| Genetic Testing Firm GeneDx Reports Narrower Q3 Loss As Revenues Surge, Lifts Annual Guidance |
GeneDx Holdings WGS stock is trading higher on Tuesday. |
benzinga.com |
2024-10-29 13:11:19 |
Czytaj oryginał (ang.) |
| GeneDx Holdings Corp. (WGS) Tops Q3 Earnings and Revenue Estimates |
GeneDx Holdings Corp. (WGS) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of a loss of $0.19 per share. This compares to loss of $0.82 per share a year ago. |
zacks.com |
2024-10-29 12:10:16 |
Czytaj oryginał (ang.) |
| GeneDx Reports Third Quarter 2024 Financial Results and Business Highlights |
STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx Holdings Corp. (Nasdaq: WGS) today reported its financial results for the third quarter of 2024. |
businesswire.com |
2024-10-29 10:00:00 |
Czytaj oryginał (ang.) |
| Groundbreaking GUARDIAN Study Shows Benefits of Adding Genome Sequencing to Newborn Screening; Augments and Improves Standard Newborn Screening |
STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that JAMA, the Journal of the American Medical Association, published peer-reviewed research from the GUARDIAN (Genomic Uniform-screening Against Rare Diseases In All Newborns) study, the largest study of its kind to explore the utility of whole genome sequencing (WGS) to identify 255 early onset genetic conditions in newborns from a diverse populatio. |
businesswire.com |
2024-10-24 15:10:00 |
Czytaj oryginał (ang.) |